Cephalon kept at neutral by Merrill

Merrill Lynch analyst Gregg Gilbert maintained Cephalon, Inc. at neutral after the company received final approval for Fentora, its follow-on to Actiq for breakthrough cancer pain. Cephalon expects the drug to be available during the first week of October, in line with the analyst's expectations. Merrill will closely monitor prescription data in the coming weeks and months to assess the Fentora launch. Shares of the Frazer, Pa.-based pharmaceutical company were up $1.82, or 3.09%, at $60.72. (Nasdaq: CEPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.